Introduction:
It aimed to investigate the expression of SUMO1/Sentrin specific peptidase 1 (SENPl) in patients with acute myeloid leukemia (AML) and its significance in the development of AML.

Material and methods:
Patients with AML, hematological malignancies, and non-neoplastic hematological diseases were selected as the experimental subjects, and they were divided into initial diagnosis subjects (n=32), recurrence subjects (n=8), and remission subjects (n=22) according to their conditions. Meanwhile, patients with non-neoplastic hematological diseases were selected as the controls (n=30). The expression of SENP1 mRNA and protein in bone marrow samples of different groups were detected. The impacts of SENP1 silencing on cell multiplication and cycle were observed.

Results:
The expression of SENP1 from low to high was the controls, the initial diagnosis subjects, the remission subjects, and the recurrence subjects. The incidence of adverse conditions was the lowest in the initial diagnosis subjects, followed by the remission subjects and the recurrence subjects. The proliferation of U937 decreased after SENP1 knockdown, suggesting that SENP1 has a major role in AML cell multiplication. In addition, the apoptosis rate of U937 was increased after SENP1 knockdown. The overall survival (OS) and disease-free survival (DFS) were ranked as: recurrence subjects < initial diagnosis subjects < remission subjects < controls.

Conclusions:
This article preliminarily confirmed the high expression of biomarker SENPl in AML patients, and found that it was related to the clinical characteristics and prognosis of AML patients.